Mineralocorticoid Receptor Antagonist for Renal Protection

REFERENCES

• Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 2010;160:1273–1292.
   PubMed Web of Science ®Google Scholar
• KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(Suppl. 2):S12–S154.
   Google Scholar
• MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553.
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1–9.
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–1697.
   PubMed Web of Science ®Google Scholar
• Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 1982;49:1561–1563.
   PubMed Web of Science ®Google Scholar
• Balcells E, Meng QC, Johnson Jr WH, Oparil S, Dell’Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol. 1997;273(4 Pt 2):H1769–H1774.
   PubMed Web of Science ®Google Scholar
• Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364–2372.
   PubMed Web of Science ®Google Scholar
• Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159–172.
   PubMed Web of Science ®Google Scholar
• Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063–1068.
   PubMed Web of Science ®Google Scholar
• Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209–F220.
   PubMed Web of Science ®Google Scholar
• Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006;70:1914–1919.
   PubMed Web of Science ®Google Scholar
• Shah SV. Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int. 1989;35:1093–1106.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Rupérez M, Esteban V, . Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006;21:16–20.
   PubMed Web of Science ®Google Scholar
• Lai L, Pen A, Hu Y, . Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. Life Sci. 2007;81:570–576.
   Google Scholar
• Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67–73.
   PubMed Web of Science ®Google Scholar
• Xavier FE, Aras-López R, Arroyo-Villa I, . Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol. 2008;154:1225–1235.
   Google Scholar
• Alzamora R, Marusic ET, Gonzalez M, Michea L. Nongenomic effect of aldosterone on Na+, K+-adenosine triphosphatase in arterial vessels. Endocrinology. 2003;144:1266–1272.
   Google Scholar
• Wehling M, Ulsenheimer A, Schneider M, Neylon C, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: Subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun. 1994;204:475–481.
   PubMed Web of Science ®Google Scholar
• Wehling M, Bauer MM, Ulsenheimer A, Schneider M, Neylon CB, Christ M. Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun. 1996;223:181–186.
   PubMedGoogle Scholar
• Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: Involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995;213:123–129.
   Google Scholar
• Funder JW. Aldosterone and mineralocorticoid receptors: Orphan questions. Kidney Int. 2000;57:1358–1363.
   Google Scholar
• Rafiq K, Nakano D, Ihara G, . Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens. 2011;29:290–298.
   Google Scholar
• Shibata S, Fujita T. The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep. 2011;13:109–115.
   Google Scholar
• Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis. 2008;51:199–211.
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106–2112.
   PubMed Web of Science ®Google Scholar
• van den Meiracker AH, Baggen RG, Pauli S, . Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285–2292.
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, . Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836.
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–542.
   PubMed Web of Science ®Google Scholar
• Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925–926.
   PubMed Web of Science ®Google Scholar
• Furumatsu Y, Nagasawa Y, Tomida K, . Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59–67.
   PubMed Web of Science ®Google Scholar
• Tylicki L, Rutkowski P, Renke M, . Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486–493.
   PubMed Web of Science ®Google Scholar
• Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116–2123.
   PubMed Web of Science ®Google Scholar
• Epstein M, Williams GH, Weinberger M, . Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940–951.
   PubMed Web of Science ®Google Scholar
• Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One. 2011;6:e26904.
   PubMed Web of Science ®Google Scholar
• Ando K, Ohtsu H, Arakawa Y, . Rationale and design of the eplerenone combination versus conventional agents to lower blood pressure on urinary antialbuminuric treatment effect (EVALUATE) trial. Hypertens Res. 2010;33:616–621.
   Google Scholar
• Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084–1093.
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension. 2007;49:355–364.
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Habibi J, Wei Y, . Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009;296:F1013–F1022.
   Google Scholar
• Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2009;3:CD007004.
   Google Scholar
• Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;4:CD006257.
   Google Scholar
• Pitt B, Zannad F, Remme WJ, . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551.
   PubMed Web of Science ®Google Scholar
• Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418–424.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, . Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar
• Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2006;20:2641–2650.
   Google Scholar